Shandong Pharmaceutical Glass: Intends to issue shares to specific targets, controlling rights or changes.

Shandong Pharma Glass announced that the company plans to issue A-shares to specific investors. Due to the adjustment of the issuance plan and updated financial data, the company signed a supplementary agreement with China National Pharmaceutical Group and its subsidiary Shandong Yaixin, revising the pricing reference date. After the issuance is completed, China National Pharmaceutical Group and Shandong Yaixin will collectively hold 199,084,233 shares, accounting for 23.08% of the total share capital. The controlling shareholder of the company will be changed to China National Pharmaceutical Group, the actual controller will be changed to the State-owned Assets Supervision and Administration Commission (SASAC). This issuance still requires approval from the state-owned assets department, approval from the shareholders' meeting, review by the Shanghai Stock Exchange, and registration with the China Securities Regulatory Commission.